title: Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome.
abstract: BACKGROUND
  Some controlled trials have shown significant differences in short-term clinical outcomes between poractant alfa and beractant in infants with respiratory distress syndrome (RDS). There is, however, no study showing the differences in long-term outcomes with these treatments.
  
  
  OBJECTIVE
  To determine and compare the neurodevelopmental outcomes of preterm infants with RDS treated with poractant alfa or beractant at 2 years of age.
  
  
  METHODS
  This was a prospective, longitudinal, single-center cohort study of infants born at ≤ 1,500 g and/or ≤ 32 weeks between 2008 and 2009 who received either poractant alfa (n = 113) or beractant (n = 102) for RDS. Neurological and developmental assessments were performed at a corrected age of 18 to 24 months.
  
  
  RESULTS
  About 33 of 113 infants (29.2%) in the poractant alfa group had neurodevelopmental impairment compared with 36 of 102 (35.2%) in the beractant group, and the results did not differ between the groups (p = 0.339). Similarly, no significant difference was found in the percentage of infants with cerebral palsy (11.5 vs. 16.7%, respectively; p = 0.275).
  
  
  CONCLUSIONS
  Our findings suggest that poractant alfa and beractant are similar in terms of neurodevelopmental outcomes when used for the treatment of RDS in preterm infants.
authors.affiliation: Department of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Eras
authors.affiliation: Department of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
authors.forename: Evrim Alyamac
authors.initials: EA
authors.lastname: Dizdar
authors.affiliation: Department of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
authors.forename: Gozde
authors.initials: G
authors.lastname: Kanmaz
authors.affiliation: Department of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
authors.forename: Nilufer
authors.initials: N
authors.lastname: Guzoglu
authors.affiliation: Department of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
authors.forename: Hatice Tatar
authors.initials: HT
authors.lastname: Aksoy
authors.affiliation: Department of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
authors.forename: Gokce Baykal
authors.initials: GB
authors.lastname: Altunkaya
authors.affiliation: Department of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
authors.forename: Fuat Emre
authors.initials: FE
authors.lastname: Canpolat
authors.affiliation: Department of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
authors.forename: Ugur
authors.initials: U
authors.lastname: Dilmen
mesh_terms: D001688:Biological Products / Q000008:administration & dosage* / Q000009:adverse effects; D002657:Child Development / Q000187:drug effects*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D008137:Longitudinal Studies; D008297:Male; D009483:Neuropsychological Tests; D010743:Phospholipids / Q000008:administration & dosage* / Q000009:adverse effects; D047928:Premature Birth / Q000188:drug therapy*; D011446:Prospective Studies; D011663:Pulmonary Surfactants / Q000008:administration & dosage* / Q000009:adverse effects; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa; C072197:beractant